Tetra Bio-Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Tetra Bio-Pharma generated cash of -$25,276,074, which is less than the previous year. Cash used in financing activities reached the amount of $29,781,295 last year. Net change in cash is therefore $2,385,199.
Cash Flow
| 2012 | -284.61K | -306.90K | 397.47K |
|---|---|---|---|
| 2013 | -143.55K | 183.84K | 0 |
| 2014 | -233.11K | 40K | 433.80K |
| 2015 | -216.72K | 201.58K | -380 |
| 2016 | -942.33K | 0 | 2.14M |
| 2017 | -3.89M | -750K | 5.61M |
| 2018 | -9.50M | -2.13M | 23.03M |
| 2019 | -17.34M | -3.68M | 9.72M |
| 2020 | -19.63M | -3.42M | 23.51M |
| 2021 | -25.27M | -2.12M | 29.78M |
TBP.TO Cash Flow Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 2.50M | 2.03M | 13.58M | 2.19M | 1.21M | 20.12K | 35.64K | 59.26K | 18.96K | 213.01K |
Operating activities | ||||||||||
Net income | -52.17M | -21.15M | -14.24M | -7.85M | -6.69M | -996.96K | -594.78K | -414.13K | -2.10M | -554.90K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 111.94K | 34.38K | 27.48K | 7.2K | 7.2K | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 1.05M | 565.61K | 232.38K | 1.42M | 2.14M | 125.4K | 73.2K | 283 | 6.40K | 75.00K |
| Deferred income tax benefit | 1.05M | 565.61K | 232.38K | 1.42M | 2.14M | 125.4K | 73.2K | 283 | 6.40K | 75.00K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | -131.45K | -57.59K | 4.29K | -19.29K | 3.01K | 78.07K |
Inventories | 0 | 0 | 0 | 44.54K | -44.54K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -25.27M | -19.63M | -17.34M | -9.50M | -3.89M | -942.33K | -216.72K | -233.11K | -143.55K | -284.61K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -100K | -100K |
Investments In Property Plant And Equipment | -1.15M | -2.15M | -254.8K | 0 | -750K | 0 | -975 | -60K | -75K | -556.90K |
Acquisitions Net | -965.5K | -1.26M | -3.43M | -2.13M | 0 | 0 | 207.57K | 0 | 0 | 0 |
Cash generated by investing activities | -2.12M | -3.42M | -3.68M | -2.13M | -750K | 0 | 201.58K | 40K | 183.84K | -306.90K |
Financing activities | ||||||||||
Common Stock Issued | 26.30M | 24.64M | 8.05M | 22.89M | 1.47M | 1.53M | 0 | 501.3K | 0 | 419.65K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 29.78M | 23.51M | 9.72M | 23.03M | 5.61M | 2.14M | -380 | 433.80K | 0 | 397.47K |
Net Change In Cash | 2.38M | 463.01K | -11.54M | 11.39M | 974.47K | 1.19M | -15.51K | 240.69K | 40.29K | -194.04K |
Cash at end of period | 4.88M | 2.50M | 2.03M | 13.58M | 2.19M | 1.21M | 20.12K | 299.95K | 59.26K | 18.96K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |